Camp4 Therapeutics Corporation - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CAMP Nasdaq 2830 www.camp4tx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Camp4 Therapeutics Corporation

CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Oct 29th, 2026 7:00 am
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union - Oct 27th, 2026 6:00 am
CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease - Oct 20th, 2026 9:04 am
CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference - Oct 14th, 2026 6:00 am
CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002 - Sep 28th, 2026 1:02 pm
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder - Sep 10th, 2026 5:33 am
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026 - Sep 8th, 2026 2:05 pm
CAMP4 to Participate in Upcoming Investor Conferences - Sep 1st, 2026 2:05 pm
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates - Aug 13th, 2026 4:50 pm
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights - Aug 13th, 2026 2:05 pm
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement - Aug 4th, 2026 5:00 am
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates - Aug 3rd, 2026 4:45 pm
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder - Jul 27th, 2026 5:00 am
New Strong Sell Stocks for July 16th - Jul 16th, 2026 2:32 am
Is CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Undervalued Ahead of Key CMP-002 Clinical Development Milestones? - Jul 2nd, 2026 2:06 pm
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors - Jul 1st, 2026 5:00 am
Here's Why We're Not Too Worried About Camp4 Therapeutics' (NASDAQ:CAMP) Cash Burn Situation - Jun 6th, 2026 6:57 am